{"page_content": "ESG Report 2023\nGlobal Access \nAgios' Global Managed Access Program (GMAP) provides a \npathway for adult PK deficiency patients receiving care in the EU and Great Britain to have access to PYRUKYND\u00ae (mitapivat) at no charge to the patient. PYRUKYND\u00ae is approved in these geographies but not currently commercially available. Healthcare providers may submit an inquiry on behalf of their patients to Agios for consideration.\nList of products on the WHO List of Prequalified Medicinal \nProducts as part of its Prequalification of Medicines  \nProgramme (PQP)  \nSASB: HC-BP-240A.2\nGiven the focus on rare disease medications,  \nAgios\u2019 products do not qualify for the WHO List of Prequalified \nMedicinal Products.\nNumber of settlements of Abbreviated New Drug Application \n(ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period  \nSASB: HC-BP-240B.1\nNone.Access to Medicines  and Affordable Pricing Strategy (continued)\nOur Pledge\nWe have pledged to price our medicines in a way that reflects the \nbenefits to patients, caregivers, the healthcare system and society and allows us to help as many people as possible today while investing in innovation to help even more people tomorrow.\nAs part of our commitment, we are not taking any price increases  \non PYRUKYND\u00ae for five years after FDA approval.\nJonathan, living with PK deficiency,  \nand his mom AlejandraInfo for EU and GB Healthcare Providers\n14", "metadata": {"source": "NASDAQ_AGIO_2022.pdf", "page": 13, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}